vemurafenib,cobimetinib,atezolizumab
roche,exelixis
['melanoma']
24 patients required steroids. 33/60 discontinued due to pod, 9 due to adverse events. #melanoma #asco22 
Melanoma+Cell Therapy Oncologist @MSKCancerCenter| Cornell/DukeMed/ MGH IM/MSKCC Onc alum | FCOI: https://t.co/kwtet64Pe4